BALTIMORE–(BUSINESS WIRE)–Aug 10, 2021–
MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (“MyMD” or “the Firm”), a medical stage pharmaceutical firm dedicated to extending wholesome lifespan by specializing in growing two therapeutic platforms, at the moment introduced that the US Patent and Trademark Workplace (USPTO) has issued U.S. Patent No. 11,085,047 titled “Artificial Cannabinoid Compounds for the Remedy of Substance Dependancy and Different Problems.”
The patent protects the Firm’s drug candidate Supera-CBD, an artificial cannabidiol spinoff that targets cannabinoid receptor sort 2 (CB2) for the therapy of neuroinflammatory and neurodegenerative illnesses. It additionally protects pharmaceutical compositions containing the Supera-CBD compound. Supera-CBD is being developed to deal with nervousness, persistent ache, habit, and seizures, and is on a path towards human medical trials as a remedy for epilepsy, adopted by persistent ache.
“Supera-CBD has the potential to deal with the numerous unmet want for drugs to deal with stimulant addictions, particularly cocaine, methamphetamine and opioids, which presently haven’t any permitted therapy,” mentioned Chris Chapman, M.D., President, Director and Chief Medical Officer of MyMD. “This primary patent for Supera-CBD will assist our discovery efforts as we transfer ahead with this platform as a significant focus for our Firm. It additionally diversifies and strengthens our rising mental property place, which already comprises 11 granted patents for our MYMD-1 drug platform.”
Supera-CBD is a non-toxic, artificial, preclinical cannabidiol spinoff that has been proven in in vitro research to be roughly 7-8x more practical than plant-derived CBD in inhibiting MAO-A and MAO-B enzymes, and greater than 3x more practical than plant-derived CBD in inhibiting CB2. These superior efficacies improve Supera-CBD’s therapeutic potential to deal with ache, irritation, and neurodegeneration, in addition to substance habit.
“Supera-CBD reveals nice promise that it might present all the advantages of plant-based CBD, at a stronger and extra environment friendly stage,” mentioned Adam Kaplin, M.D., Ph.D., Chief Scientific Officer for MyMD. “We’re wanting to see this drug transfer ahead to assist the numerous who’ve long-awaited the aid that we imagine it might present. By addressing an unmet want for pharmaceutical cannabinoids, Supera-CBD is positioned to turn out to be a prescription drug different to unregulated CBD.”
About MyMD Prescribed drugs, Inc.
MyMD Prescribed drugs, Inc. (Nasdaq: MYMD) is a medical stage pharmaceutical firm dedicated to extending wholesome lifespan in people by specializing in growing two therapeutic platforms. MYMD-1 is a drug platform primarily based on a medical stage small molecule that regulates the immunometabolic system to manage TNF-α and different pro-inflammatory cytokines. MYMD-1 is being developed to deal with autoimmune illnesses, together with these presently handled with non-selective TNF-α blocking medication, and getting older and longevity. The Firm’s second drug platform, Supera-CBD, relies on a novel artificial spinoff of cannabidiol (CBD) that targets quite a few key receptors together with CB2 and opioid receptors and inhibits monoamine oxidase. Supera-CBD is being developed to deal with the quickly rising CBD market, that features FDA permitted medication and CBD merchandise not presently regulated as a drug. For extra info, go to www.mymd.com.
Cautionary Assertion Concerning Ahead-Wanting Statements
This press launch could include forward-looking statements. These forward-looking statements contain identified and unknown dangers, uncertainties and different elements which can trigger precise outcomes, efficiency or achievements to be materially totally different from any anticipated future outcomes, efficiency, or achievements. Ahead-looking statements converse solely as of the date they’re made and none of MyMD nor its associates assume any obligation to replace forward-looking statements. Phrases comparable to “anticipate,” “imagine,” “might,” “estimate,” “count on,” “could,” “plan,” “will,” “would” and different comparable expressions are supposed to determine these forward-looking statements. Essential elements that might trigger precise outcomes to vary materially from these indicated by such forward-looking statements embody, with out limitation: the timing of, and MyMD’s means to, receive and preserve regulatory approvals for medical trials of MyMD’s pharmaceutical candidates; the timing and outcomes of MyMD’s deliberate medical trials for its pharmaceutical candidates; the quantity of funds MyMD requires for its pharmaceutical candidates; elevated ranges of competitors; modifications in political, financial or regulatory situations typically and within the markets during which MyMD operates; MyMD’s means to retain and appeal to senior administration and different key staff; MyMD’s means to rapidly and successfully reply to new technological developments; MyMD’s means to guard its commerce secrets and techniques or different proprietary rights, function with out infringing upon the proprietary rights of others and forestall others from infringing on MyMD’s proprietary rights; and the influence of the continued COVID-19 pandemic on MyMD’s outcomes of operations, marketing strategy and the worldwide financial system. A dialogue of those and different elements with respect to MyMD is ready forth within the Quarterly Report on Type 10-Q for the quarterly interval ended March 31, 2021, filed by MyMD on Might 18, 2021. Ahead-looking statements converse solely as of the date they’re made and MyMD disclaims any intention or obligation to revise any forward-looking statements, whether or not on account of new info, future occasions or in any other case.
View supply model on businesswire.com:https://www.businesswire.com/news/home/20210810005909/en/
CONTACT: Investor Contact:
KEYWORD: UNITED STATES NORTH AMERICA MARYLAND
INDUSTRY KEYWORD: BIOTECHNOLOGY PHARMACEUTICAL HEALTH CLINICAL TRIALS
SOURCE: MyMD Prescribed drugs, Inc.
Copyright Enterprise Wire 2021.
PUB: 08/10/2021 02:30 PM/DISC: 08/10/2021 02:32 PM
Copyright Enterprise Wire 2021.